By now you’ve heard the news. On Tuesday, April 13, the U.S. Centers for Disease Control and Food and Drug Administration cited six reports of patients developing blood clots after
By now you’ve heard the news. On Tuesday, April 13, the U.S. Centers for Disease Control and Food and Drug Administration cited six reports of patients developing blood clots after
Moderna (MRNA) stock currently sits 30% below the yearly highs reached in early February. Jefferies analyst Michael Yee credits the pullback to various reasons, including a “risk-off tape and rotation
Moderna, Inc. has won another order for the supply of 7 million doses of its COVID-19 vaccine to the Philippines. Moderna (MRNA) said that the new supply agreement for its
Let’s talk about the economy and COVID-19. Normally, this is a subject that will dwell on the economic disaster of the past year – the sharp recession last winter, the
Moderna (MRNA) has been one of the past year’s most successful stories. The change between the high-flying biotech’s standing a year ago compared to its current position, was easy to
